Effect of the selective CCKb receptor antagonist LY288513 on conditioned fear stress in rats

European Journal of Pharmacology

Volumn 300, Issue 1-2, 1996, Pages 25-31

  Izumi, Takeshi ^a   Inoue, Takeshi ^a   Tsuchiya, Kiyoshi ^a   Hashimoto, Shinji ^a   Ohmori, Tetsuro ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Anxiety; CCK (cholecystokinin); CCK receptor antagonist; CCKB receptor; Conditioned fear stress; LY288513 ((4S,5R) N (4 bromophenyl) 3 oxo 4,5 diphenyl 1 pyrazolidinecarboxamide)

Indexed keywords

1 (4 BROMOPHENYLAMINOCARBONYL) 4,5 DIPHENYL 3 PYRAZOLIDINONE; 1-(4-BROMOPHENYLAMINOCARBONYL)-4,5-DIPHENYL-3-PYRAZOLIDINONE; CHOLECYSTOKININ RECEPTOR; DRUG DERIVATIVE; HORMONE ANTAGONIST; LORGLUMIDE; LOXIGLUMIDE; PROGLUMIDE; PYRAZOLE DERIVATIVE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; FEAR; INSTRUMENTAL CONDITIONING; MALE; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; STRESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DRUG SELECTIVITY; ELECTRIC SHOCK; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; FEAR; HORMONE ANTAGONISTS; MALE; PROGLUMIDE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLECYSTOKININ; STRESS;

EID: 0029665970     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00859-4     Document Type: Article

References (29)

1. Carter, R.B., 1991, Differentiating analgesic and non-analgesic drug activities on rat hot plate: effect of behavioral endpoint, Pain 47, 211.
2. Chopin, P. and M. Briley, 1993, The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze, Psychopharmacology 110, 409.
3. De Montigny, C., 1989, Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers, Arch. Gen. Psychiatry 46, 511.
4. Dourish, C.T., M.F. O'Neill, J. Coughlan, S.J. Kitchener, D. Hawley and S.D. Iversen, 1990, The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat, Eur. J. Pharmacol. 176, 35.
5. Fanselow, M.S., 1980, Conditional and unconditional components of post-shock freezing, Pavlov J. Biol. Sci. 15, 177.
6. Fanselow, M.S. and F.J. Helmstetter, 1988, Conditional analgesia, defensive freezing, and benzodiazepines, Behav. Neurosci. 102, 233.
7. Hashimoto, S., T. Inoue and T. Koyama, 1995, Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats, Pharmacol. Biochem. Behav. (in press).
8. Hendrie, C.A. and C.T. Dourish, 1990, Anxiolytic profile of the cholecystokinin antagonist devazepide in mice, Br. J. Pharmacol. 99, 138.
9. Herman, J.P., D. Guillonneau, R. Dantzer, B. Scatton, L. Semerdjian-Rouquier and M. Le Moal, 1982, Differential effects of inescapable footshocks and of stimuli previously paired with inescapable foot-shocks on dopamine turnover in cortical and limbic areas of the rat, Life Sci. 30, 2207.
10. Hughes, J., P. Boden, B. Costall, A. Domeney, E. Kelly, D.C. Horwell, J.C. Hunter, R.D. Pinnock and G.N. Woodruff, 1990, Development of a class of cholecystokinin type B antagonists having potent anxiolytic activity, Proc. Natl. Acad. Sci. USA 87, 6728.
11. Inoue, T., T. Koyama and I. Yamashita, 1993, Effect of conditioned fear stress on serotonin metabolism in the rat brain, Pharmacol. Biochem. Behav. 44, 371.
12. Inoue, T., K. Tsuchiya and T. Koyama, 1994, Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain, Pharmacol. Biochem. Behav. 49, 911.
13. Inoue, T., K. Tsuchiya and T. Koyama, 1995, Serotonergic activation reduces defensive freezing in the conditioned fear paradigm, Pharmacol. Biochem. Behav. (in press).
14. Kaken Co. and Tokyo Tanabe Co., 1990, CR1505 Investigator Brochure, p. 59.
15. Koszycki, D., B.J. Cox and J. Bradwejn, 1993, Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers, Am. J. Psychiatry 150, 1881.
16. Moran, Th., P.H. Robinson, M.S. Goldrich and P.R. Mchugh, 1986, Two brain cholecystokinin receptors: implications for behavioral actions, Brain Res. 362, 175.
17. Ohmori, T., T. Abekawa, A. Muraki and T. Koyama, 1994, Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine, Pharmacol. Biochem. Behav. 48, 587.
18. Palmour, R.M., F.R. Ervin, J. Bradwejn and J.J. Howbert, 1991, Anxiogenic and cardiovascular effects of CCK-4 in monkeys are blocked by the CCK-B antagonist LY262691, Soc. Neurosci. Abstr. 17, 1602
19. 2 agonists, Eur. Neuropsychopharmacol. 2, 193.
20. Rasmussen, K., J.F. Czachura, M.E. Stockton and J.J. Howbert, 1993, Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons, J. Pharmacol. Exp. Ther. 264, 480.
21. Rataud, J., F. Darche, O. Piot, J.M. Stutzmann, G.A. Böhme and J.C. Blanchard, 1991, 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice, Brain Res. 548, 315.
22. Ravard, S., C.T. Dourish and S.D. Iversen, 1990, Evidence that the anxiolytic-like effects of CCK antagonists devazepide and L-365,260 in the elevated plus-maze paradigm in rats are mediated by CCK receptors, Br. J. Pharmacol. 101, 576.
23. Singh, L., A.S. Lewis, M.J. Field, J. Hughes and G.N. Woodruff, 1991a, Evidence for an involvement of the brain cholecystokinin B receptor in anxiety, Proc. Natl. Acad. Sci. USA 88, 1130.
24. Singh, L., M.J. Field, J. Hughes, R. Menzies, R.J. Oles, C.A. Vass and G.N. Woodruff, 1991b, The behavioral properties of CI-988, a selective cholecystokinin B receptor antagonist, Br. J. Pharmacol. 104, 239.
25. Tsuda, A., M. Tanaka, Y. Ida, S. Tsujimaru, I. Ushijima and N. Nagasaki, 1986, Effects of preshock experience on enhancement of rat brain noradrenaline turnover induced by psychological stress, Pharmacol. Biochem. Behav. 24, 115.
26. Van der Kooy, D., S.P. Hunt, H.W.M. Steinbusch and A.A.J. Verhofstad, 1981, Separate populations of cholecystokinin and 5-hydroxytryptamine-containing neuronal cells in the rat dorsal raphe, and their contribution to the ascending raphe projections, Neurosci. Lett. 26, 25.
27. Wank, S.A., J.R. Pisegna and A. De Weerth, 1994, Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig, and human, Ann. NY Acad. Sci. 713, 49.
28. Woodruff, G.N. and J. Hughes, 1991, Cholecystokinin antagonist, Annu. Rev. Pharmacol. Toxicol. 31, 469.
29. Yaksh, T.L., T. Furui, I.S. Kanawati and V.L.W. Go, 1987, Release of cholecystokinin from rat cerebral cortex in vivo: role of GABA and glutamate receptor systems, Brain Res. 406, 207.